



Jan 10, 2024

Version 3

 Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson's. V.3

DOI

dx.doi.org/10.17504/protocols.io.4r3l27dxxg1y/v3

Katherine Brimblecombe^{1,2,3}, Stephanie J Cragg^{1,2,3}

¹Department of Physiology, Anatomy and Genetics, University of Oxford, OX1 3PT, UK;

²Oxford Parkinson's Disease Centre, University of Oxford, Oxford, United Kingdom;

³Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815



Cláudia C. Mendes

University of Oxford



Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.4r3l27dxxg1y/v3>

Collection Citation: Katherine Brimblecombe, Stephanie J Cragg 2024. Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson's. . **protocols.io** <https://dx.doi.org/10.17504/protocols.io.4r3l27dxxg1y/v3> Version created by **Cláudia C. Mendes**

**Manuscript citation:**

Brimblecombe KR, Connor-Robson N, Bataille CJR, Roberts BM, Gracie C, O'Connor B, Te Water Naude R, Karthik G, Russell AJ, Wade-Martins R, Cragg SJ. *Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's*. Eur J Neurosci. 2023 Nov 8. doi: 10.1111/ejn.16180. Epub ahead of print. PMID: 37941514.

License: This is an open access collection distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this collection and it's working

Created: January 10, 2024

Last Modified: January 10, 2024

Collection Integer ID: 93218

Keywords: Calb1, L-type calcium channel, Parkinson's disease, dopamine D2 receptor, dopamine release, dopamine transporter, sex differences, striatum, synuclein, type calcium channel inhibitor isradipine, inhibition of striatal dopamine release, striatal dopamine release, risk factors for parkinson, parkinson, inhibition

Funders Acknowledgements:

Aligning Science Across Parkinson's

Grant ID: ASAP-020370

Abstract

This collection contains five protocols detailing methods used in **Brimblecombe, K.R. et al. (2023)** *Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson's*.

Troubleshooting



Files

 SEARCH

Protocol



NAME

Fast-scan cyclic voltammetry to assess dopamine release in ex vivo mouse brain slices

VERSION 1

CREATED BY



Cláudia C. Mendes
University of Oxford

OPEN →

Protocol



NAME

Making Carbon-Fibre Microelectrode (CFM) for electrochemical recordings of monoamines in ex vivo mouse brain slices

VERSION 2

CREATED BY



Cláudia C. Mendes
University of Oxford

OPEN →

Protocol



NAME

Synthesis of 1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione (CP8)

VERSION 2

CREATED BY



Cláudia C. Mendes
University of Oxford

OPEN →

Protocol



NAME

Stock solutions of cocaine, isradipine, nomifensine, lidocaine, DH β E, CP8, L-741,626, and water-soluble cholesterol

VERSION 1

CREATED BY



Cláudia C. Mendes
University of Oxford

OPEN →

Protocol



NAME

Western blot in homogenised mouse brain samples

VERSION 2

CREATED BY



Cláudia C. Mendes
University of Oxford

OPEN →